All In Biotech

Drug Trial Radar · NCT03292536

Merestinib on Bone Metastases in Subjects With Breast Cancer

An Exploratory Phase 1B Study to Assess the Effects of Merestinib on Bone Metastases in Subjects With Breast Cancer

Last checked: Nov 19, 2026Latest source record: Jan 8, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

Terminated

Status

Terminated

Enrollment

2

Actual

Start

Jan 11, 2018

Primary completion

Jun 24, 2019

Study completion Jun 24, 2019

Sponsor

Lead sponsor
University of UtahAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Eli Lilly and Company
First posted
Sep 25, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an open label, pharmacodynamics, intrapatient dose escalation phase 1B study.

Conditions

  • Bone Metastases
  • Breast Cancer

Interventions

  • MerestinibDrug

    \*The merestinib does escalation timing will depend on the schedule of the other anticancer regimen\* Subjects will receive merestinib 40mg PO Qday (dose level 1) for 2 to 4 weeks followed by 80mg PO daily (dose level 2) for 4 to 10 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Adverse Events that OccurTime frame: 12 weeks, checked at every visit in that time period
  2. Change in urinary N-telopeptide levelTime frame: 12 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Huntsman Cancer Institute

    Salt Lake City, Utah

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.